- Home
- APLM vs PRSO Comparison
APLM vs PRSO Comparison
Compare APLM & PRSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- PRSO
- Stock Information
- Founded
- APLM 2016
- PRSO 2008
- Country
- APLM United States
- PRSO United States
- Employees
- APLM N/A
- PRSO N/A
- Industry
- APLM Blank Checks
- PRSO Semiconductors
- Sector
- APLM Finance
- PRSO Technology
- Exchange
- APLM Nasdaq
- PRSO Nasdaq
- Market Cap
- APLM 6.9M
- PRSO 6.1M
- IPO Year
- APLM N/A
- PRSO 2001
- Fundamental
- Price
- APLM $6.06
- PRSO $0.98
- Analyst Decision
- APLM
- PRSO Strong Buy
- Analyst Count
- APLM 0
- PRSO 1
- Target Price
- APLM N/A
- PRSO $3.00
- AVG Volume (30 Days)
- APLM 28.0K
- PRSO 357.3K
- Earning Date
- APLM 08-13-2025
- PRSO 08-11-2025
- Dividend Yield
- APLM N/A
- PRSO N/A
- EPS Growth
- APLM N/A
- PRSO N/A
- EPS
- APLM N/A
- PRSO N/A
- Revenue
- APLM $198,000.00
- PRSO $15,626,000.00
- Revenue This Year
- APLM $415.15
- PRSO $0.69
- Revenue Next Year
- APLM N/A
- PRSO $35.21
- P/E Ratio
- APLM N/A
- PRSO N/A
- Revenue Growth
- APLM N/A
- PRSO 35.50
- 52 Week Low
- APLM $4.47
- PRSO $0.52
- 52 Week High
- APLM $35.98
- PRSO $2.34
- Technical
- Relative Strength Index (RSI)
- APLM 48.70
- PRSO 43.62
- Support Level
- APLM $5.11
- PRSO $0.93
- Resistance Level
- APLM $6.56
- PRSO $1.03
- Average True Range (ATR)
- APLM 0.49
- PRSO 0.07
- MACD
- APLM 0.00
- PRSO -0.02
- Stochastic Oscillator
- APLM 63.42
- PRSO 16.27
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About PRSO Peraso Inc.
Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz, to 300 GHz. Geographically the company generates revenue from the United States, Hong Kong, Taiwan, and the Rest of the World.